[COMPANY LOGO OMITTED]
CONTACT:
Kara Stancell, Investor Relations & Corporate Communications, (602) 808-3854
MEDICIS REPORTS FOURTH QUARTER AND YEAR-END FISCAL 2004 FINANCIAL RESULTS
SCOTTSDALE, Arizona--August 24, 2004--Medicis (NYSE:MRX) today announced fourth
quarter fiscal 2004 net revenue growth of approximately 32% to $88.0 million
with "if-converted" net income of $24.5 million, or $0.37 per diluted share. The
Company reported Generally Accepted Accounting Principles ("GAAP") net income
for the fourth quarter fiscal 2004 of $23.7 million. Included in net income is a
tax-effected loss of approximately $249,000 associated with the loss on sale of
certain product rights. The Company reported fourth quarter fiscal 2003 net
revenues of $66.7 million with net income of $17.1 million, or $0.30 per diluted
share, absent a $3.3 million tax-effected special charge reported during the
fourth quarter of fiscal 2003 associated with a research and development
collaboration. Including the $3.3 million tax-effected special charge reported
during the fourth quarter of fiscal 2003, Medicis reported GAAP net income of
$13.9 million, or $0.24 per diluted share for fourth quarter fiscal 2003.
For fiscal year 2004, Medicis reported net revenue growth of approximately 23%
to $303.7 million with "if-converted" net income of $73.2 million, or $1.13 per
diluted share, absent a $37.5 million tax-effected loss associated with the
early extinguishment of debt reported in the first quarter of fiscal 2004 and
absent a $1.6 million tax-effected special charge associated with a research and
development collaboration reported in the second quarter of fiscal 2004.
Included in net income is a tax-effected loss of approximately $249,000
associated with the loss on sale of certain product rights. Including the
special charges and the loss on sale of certain product rights, the Company
reported GAAP net income of $30.8 million, or $0.52 per diluted share for fiscal
2004.
Comparatively, Medicis reported fiscal 2003 net revenues of $247.5 million with
net income of $63.5 million, or $1.13 per diluted share, absent a $12.2 million
tax-effected special charge reported during fiscal 2003 associated with research
and development collaborations. Including the tax-effected special charge of
$12.2 million reported during fiscal 2003, the Company reported GAAP net income
of $51.3 million, or $0.91 per diluted share for fiscal 2003.
Fourth quarter and fiscal year-end 2004 diluted per share amounts are calculated
using the "if-converted" method of accounting in accordance with GAAP due to the
outstanding 2.5% Convertible Senior Notes meeting the criteria for conversion,
regardless of whether the bondholders actually convert their bonds into shares.
For the year ended June 30, 2004, the dilutive shares relative to the
convertible notes do not impact GAAP earnings per share, as they are
anti-dilutive. Fourth quarter and fiscal year-end 2003 diluted per share amounts
do not reflect the "if-converted" method, as the criteria for conversion had not
been met.
(more)
"We are pleased to announce the completion of the strongest quarter and fiscal
year in the Company's history," said Jonah Shacknai, Chairman and Chief
Executive Officer of Medicis. "Fiscal 2004 was another noteworthy year for
Medicis, with several significant milestone achievements, including exceptional
sales growth through the launch of RESTYLANE(R), exceeding $125 million in cash
flow from operations, surpassing $80 million in revenues for the first time
during one quarter, and accumulating over $1 billion in assets. We express our
gratitude to the physicians and the exceptional Medicis team for their support
as we continue our expansion into the aesthetics market and remain focused on
our commitment to increasing shareholder value in fiscal 2005."
Fiscal 2004 year-end net revenues increased approximately 23%, primarily as a
result of overall growth in sales of RESTYLANE(R), DYNACIN(R), LOPROX(R) and
TRIAZ(R). At the end of the fourth quarter, the Company's core brands included
DYNACIN(R), LOPROX(R), OMNICEF(R), PLEXION(R), RESTYLANE(R) and TRIAZ(R). For
fiscal 2004, core brands, including ORAPRED(R), represented approximately 87% of
total product sales. During fiscal 2004, prescription volume growth for the
Company's core brands, excluding RESTYLANE(R), increased 15% and 13% in new and
total prescriptions, respectively. The Company's gross profit margin was
approximately 85% for the fiscal 2004 year-end.
For the fourth quarter fiscal 2004, cash flow from operations was $50.5 million,
compared to $16.0 million for the fourth quarter fiscal 2003, or a 215%
increase. During fourth quarter fiscal 2004, selling, general and administrative
expenses decreased approximately 1 percentage point as a percentage of sales
compared to fourth quarter fiscal 2003, increasing approximately 27% in fourth
quarter fiscal 2004 to $30.3 million, compared to $23.9 million for fourth
quarter fiscal 2003.
Cash flow from operations for fiscal 2004 was $128.0 million, compared to $84.7
million for fiscal 2003, or a 51% increase. Selling, general and administrative
expenses for fiscal 2004 increased approximately 29% to $118.3 million,
primarily due to the incremental costs incurred with the product launch and
first U.S. commercial sales of RESTYLANE(R), which began on January 6, 2004.
Such incremental costs associated with the product launch included the hiring of
a dedicated aesthetics sales force, additional headquarters personnel to support
sales force efforts, including product management, customer service and training
personnel, expenses associated with public relations, physician training and
continuing medical education, and other administrative expenses.
During fiscal 2004, research and development expense, absent special charges,
increased approximately 50% to $14.1 million for the year, primarily due to the
advancement of the Company's research and development pipeline. Depreciation and
amortization expense for fiscal 2004 increased approximately 66% to $16.8
million, primarily due to the amortization of the purchase price for the
exclusive rights to RESTYLANE(R) in the United States and Canada.
The Company's previously released fiscal year 2005 revenue and earnings guidance
remains unchanged and is as follows: fiscal year 2005 revenues of approximately
$365 million and earnings per share guidance of approximately $1.42; first
quarter fiscal year 2005 (for the quarter ending September 30, 2004) revenue
guidance of approximately $85 million and earnings per share guidance of
approximately $0.29; second quarter fiscal year 2005 (for the quarter ending
December 31, 2004) revenue guidance of approximately $89 million and earnings
per share guidance of approximately $0.35; third quarter fiscal 2005 (for the
quarter ending March 31, 2005) revenue guidance of approximately $93 million and
earnings per share guidance of approximately $0.36; and fourth quarter fiscal
year 2005 (for the quarter ending June 30, 2005) revenue guidance of
approximately $98 million and earnings per share guidance of approximately
$0.42. At the time of this disclosure, Medicis believes these objectives are
attainable based upon information currently available to the Company. The
Company's business is subject to all risk factors outlined in the Company's most
recent annual report on Form 10-K, its Form S-3 registration statement and other
filed documents with the Securities and Exchange Commission. At the time of this
release, the Company cannot, among other things, assess the forthcoming results
(more)
of the Company's research and development projects and the risks associated with
the FDA approval process, risks associated with significant competition within
the Company's industry, risks associated with changes in laws, risks related to
general economic conditions, including interest rate fluctuations, nor can the
Company validate its assumptions of the full impact on its business of the
approval of competitive generic versions of the Company's core brands, or any
future competitive product approvals that may affect the Company's brands.
Additionally, Medicis may acquire and/or license products or technologies from
third parties to enter into new strategic markets. The Company periodically
makes up-front, non-refundable payments to third parties for research and
development work which has been completed and periodically makes additional
non-refundable payments for the achievement of various milestones. There can be
no certainty which periods these potential payments could be made, or if any
payments such as these will be made at all. The stated estimated future guidance
does not include the potential payments associated with any such transactions.
Medicis is the leading independent specialty pharmaceutical company in the
United States focusing primarily on the treatment of dermatological and
podiatric conditions and aesthetics medicine. Medicis has leading branded
prescription products in a number of therapeutic categories, including acne,
eczema, fungal infections, psoriasis, rosacea, seborrheic dermatitis and skin
and skin-structure infections. The Company's products have earned wide
acceptance by both physicians and patients due to their clinical effectiveness,
high quality and cosmetic elegance.
The Company's products include the prescription brands RESTYLANE(R), DYNACIN(R)
(minocycline HCl), LOPROX(R) (ciclopirox), OMNICEF(R) (cefdinir), PLEXION(R)
(sodium sulfacetamide/sulfur), TRIAZ(R) (benzoyl peroxide), LIDEX(R)
(fluocinonide), and SYNALAR(R) (fluocinolone acetonide), the over-the-counter
brand ESOTERICA(R), and BUPHENYL(R) (sodium phenylbutyrate), a prescription
product indicated in the treatment of Urea Cycle Disorder. For more information
about Medicis, please visit the Company's website at www.medicis.com.
Except for historical information, this press release includes "forward-looking
statements" within the meaning of the Securities Litigation Reform Act. All
statements included in this press release that address activities, events or
developments that Medicis expects, believes or anticipates will or may occur in
the future are forward-looking statements. This includes earnings estimates,
future financial performance and other matters. These statements are based on
certain assumptions made by Medicis based on its experience and perception of
historical trends, current conditions, expected future developments and other
factors it believes are appropriate in the circumstances. Such statements are
subject to a number of assumptions, risks and uncertainties, many of which are
beyond the control of Medicis. Any such projections or statements include the
current views of Medicis with respect to future events and financial
performance. No assurances can be given, however, that these events will occur
or that such results will be achieved. Medicis cannot validate its assumptions
of the full impact on its business of the approval of competitive generic
versions of its core brands, including DYNACIN(R) Tablets and/or LOPROX(R), or
any future competitive product approvals that may affect its brands. Also, there
are a number of additional important factors that could cause actual results to
differ materially from those projected, including the anticipated size of the
markets, the availability of product supply, the receipt of required regulatory
approvals, the ability to realize anticipated synergies and benefits of the
Q-Med transactions, the risks and uncertainties normally incident to the
pharmaceutical industry, dependence on sales of key products, the uncertainty of
future financial results and fluctuations in operating results, dependence on
Medicis' strategy including the uncertainty of license payments and/or other
payments due from third parties, the timing and success of new product
development by Medicis or third parties, product introductions, the risks of
pending or future litigation, and other risks described from time to time in
Medicis' SEC filings including its Annual Report on Form 10-K for the year ended
June 30, 2003. There can be no assurance as to when or if any of the holders of
the Notes will have the right to convert or if the Notes will be converted, and
what impact the increase in the number of shares outstanding will have on its
(more)
results of operations. Forward-looking statements represent the judgment of
Medicis' management as of the date of this release, and Medicis disclaims any
intent or obligation to update any forward-looking statements.
NOTE: Full prescribing information for any Medicis prescription product is
available by contacting the Company. OMNICEF(R) is a registered trademark of
Abbott Laboratories, Inc. under a license from Fujisawa Pharmaceutical Co., Ltd.
RESTYLANE(R) is a registered trademark of HA North American Sales AB, a
subsidiary of Medicis Pharmaceutical Corporation. All other marks (or brands)
and names are the property of Medicis or its Affiliates.
Medicis
Summary Statements of Operations
(in thousands, except per share data)
Three Months Ended Year Ended
June 30, June 30,
------------------------------------- ---------------------------------------
2004 2003 2004 2003
------------------------------------- ---------------------------------------
Revenues $ 87,954 $ 66,705 $ 303,722 $ 247,539
Cost of sales 12,070 10,681 46,606 38,260
-------- -- --------- ---------
Gross profit 75,884 56,024 257,116 209,279
Operating expenses:
Selling, general and administrative 30,345(a) 23,909 118,253(a) 91,648
Research and development 4,119 8,215(b) 16,494(c) 29,568(d)
Depreciation and amortization 4,921 3,378 16,794 10,125
-------- -------- --------- ---------
Total operating expenses 39,385 35,502 151,541 131,341
Operating income 36,499 20,522 105,575 77,938
Interest expense, net (310) (408) (758) (278)
Loss on early extinguishment of debt -- -- (58,660) --
Income tax expense (12,484) (6,263) (15,317) (26,404)
-------- -- --------- ---------
Net income $ 23,705 $ 13,851 $ 30,840 $ 51,256
======== ======== ========= =========
Basic net income per common share $0.42 $0.25 $0.55 $0.94
===== ===== ===== =====
Diluted net income per common share $0.37(e) $0.24 $0.52(f) $0.91
===== ===== ===== =====
Shares used in basic net income per common share 56,889 54,343 55,618 54,376
Shares used in diluted net income per common share 66,799 56,871 59,258 56,422
Cash flow from operations $ 50,536 $ 16,035 $127,964 $ 84,667
- ------------------------------------------------------------------------------------------------------------------------------------
GAAP Net income $ 23,705 $ 13,851 $ 30,840 $ 51,256
Interest expense and associated bond offering
costs (tax-effected) 836(e) -- 3,345(f) --
Special charge for R&D (tax-effected) -- 3,279 1,575 12,225
Loss on early extinguishment of debt
(tax-effected) -- -- 37,474 --
-------- -------- --------- ---------
"If-converted" net income absent special charge
and loss on early extinguishment of debt $ 24,541 $ 17,130 $ 73,234 $ 63,481
======== ======== ========= =========
Shares used in diluted net income per common
share 66,799 56,871 65,081 56,422
Diluted net income per common share $0.37 $0.30 $1.13 $1.13
===== ===== ===== =====
- ------------------------------------------------------------------------------------------------------------------------------------
(a) Reported selling, general and administrative expenses include a special
charge of $0.4 million ($0.2 million tax-effected) relating to a loss on the
sale of certain product rights.
(b) Reported R&D expenses include a special charge of $6.0 million ($3.3 million
tax-effected) relating to a research & development collaboration.
(c) Reported R&D expenses include a special charge of $2.4 million ($1.6 million
tax-effected) relating to a research & development collaboration.
(d) Reported R&D expenses include a special charge of $20.2 million ($12.2
million tax-effected) relating to research & development collaborations.
(e) To calculate diluted earnings per share, tax-effected net interest on the
2.5% contingent convertible notes and associated bond offering costs of $836,000
is added back to GAAP net income for the three months ended June 30, 2004, and
divided by shares used in diluted net income per common share.
(f) To calculate diluted earnings per share, tax-effected net interest on the
2.5% contingent convertible notes and associated bond offering costs of
$3,345,000 is added back to GAAP net income for the year ended June 30, 2004,
and divided by shares used in diluted net income per common share. For GAAP
diluted net income per common share for the year ended June 30, 2004, the
dilutive shares relative to the convertible notes are not included as they are
anti-dilutive.
Balance Sheets
--------------
At June 30, 2004 At June 30, 2003
Assets
Cash, cash equivalents & short-term investments $634,040 $552,663
Accounts receivable, net 47,858 51,661
Inventory, net 19,540 14,005
Other current assets 32,425 27,299
------ ------
Total current assets 33,863 645,628
Property and equipment, net 5,842 3,094
Intangible assets, net 331,144 274,120
Other assets 7,535 9,999
----- -----
Total assets $1,078,384 $932,841
========== ========
Liabilities and stockholders' equity
Current liabilities $ 67,120 $ 68,847
Contingent convertible senior notes 2.5% due 2032 169,157 400,000
Contingent convertible senior notes 1.5% due 2033 283,910 --
Deferred tax liability 2,894 2,873
Stockholders' equity 555,303 461,121
------- -------
Total liabilities and stockholders' equity $1,078,384 $932,841
========== ========
Working capital $666,743 $576,781
======== ========
# # #